210 related articles for article (PubMed ID: 38062418)
1. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
Ha NY; Kim JW; Kim J
BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
[TBL] [Abstract][Full Text] [Related]
3. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
[TBL] [Abstract][Full Text] [Related]
4. Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.
Liu W; Xie Y; Li Y; Zheng L; Xiao Q; Zhou X; Li Q; Yang N; Zuo K; Xu T; Lu NH; Zhang H
BMC Gastroenterol; 2022 May; 22(1):255. PubMed ID: 35596146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: protocol for a pilot, randomized, double-blind, placebo-controlled trial.
Bhang YH; Kim KI; Kim J; Ahn J; Jung HS; Yang C; Ko SJ; Bu Y; Park JW; Park KS; Jung HJ; Lee JH; Lee BJ
Trials; 2020 Jan; 21(1):118. PubMed ID: 31996267
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
7. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
10. Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
Shih YS; Tsai CH; Li TC; Yu CJ; Chou JW; Feng CL; Wang KT; Lai HC; Hsieh CL
Phytomedicine; 2019 Mar; 56():118-125. PubMed ID: 30668332
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
12. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Hussain S; Kierkus J; Hu P; Hoffman D; Lekich R; Sloan S; Treem W
J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):226-36. PubMed ID: 24121146
[TBL] [Abstract][Full Text] [Related]
14. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
15. Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial.
Li X; Wu H; Zhang B; Chen T; Shi X; Ma J; Zhang J; Tang X; Wang F
Trials; 2022 Oct; 23(1):879. PubMed ID: 36258217
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Placebo-Controlled
Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
[TBL] [Abstract][Full Text] [Related]
17. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
[TBL] [Abstract][Full Text] [Related]
18. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Haddad I; Kierkus J; Tron E; Ulmer A; Hu P; Sloan S; Silber S; Leitz G
J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):798-807. PubMed ID: 23863328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
